Penserra Capital Management LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Penserra Capital Management LLC bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,960 shares of the biopharmaceutical company’s stock, valued at approximately $125,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in HALO. Norges Bank acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at about $60,054,000. Capital World Investors bought a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at about $35,773,000. Arrowstreet Capital Limited Partnership lifted its stake in shares of Halozyme Therapeutics by 141.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company’s stock valued at $47,470,000 after buying an additional 581,475 shares during the period. D. E. Shaw & Co. Inc. lifted its stake in shares of Halozyme Therapeutics by 171.2% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company’s stock valued at $39,750,000 after buying an additional 524,802 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at about $21,838,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $56.43, for a total transaction of $1,128,600.00. Following the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at $41,403,763.17. The trade was a 2.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey William Henderson sold 4,497 shares of the business’s stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the transaction, the director owned 28,611 shares in the company, valued at $1,727,246.07. This represents a 13.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 64,497 shares of company stock worth $3,533,884 over the last three months. Insiders own 2.40% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Leerink Partnrs cut shares of Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 13th. HC Wainwright restated a “buy” rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, May 29th. Leerink Partners cut shares of Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 price target for the company. in a research note on Tuesday, May 13th. JPMorgan Chase & Co. raised their price target on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a “neutral” rating in a research note on Monday, April 21st. Finally, Benchmark cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 7th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $62.50.

Halozyme Therapeutics Price Performance

Shares of HALO stock opened at $57.15 on Friday. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $70.51. The firm has a market capitalization of $7.04 billion, a price-to-earnings ratio of 15.20, a price-to-earnings-growth ratio of 0.38 and a beta of 1.15. The company has a quick ratio of 7.30, a current ratio of 8.39 and a debt-to-equity ratio of 3.13. The firm has a fifty day moving average of $55.03 and a 200-day moving average of $56.95.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. The company had revenue of $264.86 million during the quarter, compared to analyst estimates of $231.21 million. During the same quarter in the previous year, the business earned $0.79 EPS. The firm’s revenue was up 35.2% on a year-over-year basis. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.